Drugs / Heme Iron Polypeptide
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00318812 | May 2007 → Dec 2011 | chronic kidney disease, iron deficiency anemia | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01865175 | Jan → May 2016 | iron deficiency anemia | Milton S. Hershey Medical Center | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Heme Iron Polypeptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00318812 ↗ |
| Known as | HIP | “The purpose of this study was to determine if oral Heme Iron Polypeptide (HIP) is as effective as IV iron sucrose in the treatment of iron-deficiency anemia for patients with ND-CKD.” PMID 23514036 ↗ Mar 2013 |
| Route | Oral | “Heme iron polypeptide is a newly available formulation of oral iron which can be administered orally” NCT00318812 ↗ |